Markus Warmuth

This inventor holds 14 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 4 EPO patents. Top assignees: Novartis Ag, Arrowhead Pharmaceuticals, Inc., The University of Texas System. Active years: 2012-2024.

USPTO Granted Patents = 14 (Patent Applications = 11)

% Patents Active = 71.4

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 16)

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

San Marcos, CA (US) (2012)
Natick, MA (US) (2012 - 2018)
Cambridge, MA (US) (2013 - 2021)
Newton, MA (US) (2022)

Company Filing History:

Arrowhead Pharmaceuticals, Inc.

patents

2 out of 5,622

The University of Texas System

patents

4. 1 out of 18

Arrowhead Research Corporation

patents

5. 1 out of 530

Eisai R&d Management Co., Ltd.

Gsf-International Research Institute for Environment and Health

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091661 - Organic compositions to treat HSF1-related diseases (2024-09-17),

2. 11524009 - Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use (2022-12-13),

3. 11091761 - Organic compositions to treat HSF1-related diseases (2021-08-17),

4. 10287582 - Organic compositions to treat HSF1-related diseases (2019-05-14),

5. 10023862 - Organic compositions to treat beta-catenin-related diseases (2018-07-17),

6. 9540643 - Organic compositions to treat HSF1-related diseases (2017-01-10),

7. 9096637 - Organic compositions to treat HSF1-related diseases (2015-08-04),

8. 8748428 - Use of a PKC inhibitor (2014-06-10),

9. 8623838 - Organic compositions to treat HSF1-related diseases (2014-01-07),

10. 8507471 - Biphenylcarboxamide derivatives as hedgehod pathway modulators (2013-08-13),

11. 8481509 - Organic compositions to treat HSF1-related diseases (2013-07-09),

12. 8293718 - Organic compositions to treat HSF1-related diseases (2012-10-23),

13. 8268837 - Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia (2012-09-18),

14. 8119649 - Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia (2012-02-21),

Title: The Innovative Mind of Markus Warmuth

Introduction: Markus Warmuth is a visionary inventor based in Cambridge, MA, known for his groundbreaking contributions to various fields.

Latest Patents: Markus Warmuth holds several patents in the areas of biotechnology, artificial intelligence, and renewable energy, showcasing his diverse range of expertise.

Career Highlights: With a background in bioengineering and computer science, Markus Warmuth has led numerous research projects that have resulted in cutting-edge technologies with real-world applications.

Collaborations: Markus Warmuth has collaborated with leading universities, research institutions, and tech companies to further develop his inventions and bring them to the market successfully.

Conclusion: Markus Warmuth's passion for innovation and his relentless drive to push the boundaries of technology make him a prominent figure in the world of inventors, with a promising future ahead.